Stanford University HIV Drug Resistance Database - A curated public database designed to represent, store, and analyze the divergent forms of data underlying HIV drug resistance.

Essential Data on NNRTI DRMs

Last updated on 2016-6-20

Prevalence of NNRTI DRMs in ARV-naive and -treated patients and their contributions to reduced NNRTI susceptibility
DRM HIVDB
Score
SDRM Prevalence (%) Phenotypic Fold Resistance
ARV-Naive
(n=65080)
ARV-Treated
(n=22246)
NVP
(n=1694)
EFV
(n=1687)
ETR
(n=484)
RPV
(n=183)
K103N
60
1
36
24
21
1.3
2
Y181C
60
0.1
20
16
2.0
8
3
G190A
60
0.2
15
11
11
0.9
1.3
V106M
60
0.02
5
18
32
0.6
NA
L100I
60
0.01
4
3
14
6
7
Y188L
60
0.04
4
>50
>50
3
10
G190S
60
0.01
3
35
>50
0.9
NA
M230L
60
0.02
2
6
7
4
5
K103S
60
0.04
2
11
7
1.5
1.7
V106A
60
0.01
2
>50
7
0.4
NA
K101P
60
0
1
18
25
22
>50
Y188C
60
0.01
0.9
>50
35
NA
NA
Y181I
60
0
0.9
>50
1.4
30
24
Y181V
60
0
0.6
>50
2
>50
NA
G190E
60
0.03
0.5
>50
>50
>50
27
Y188H
60
0.03
0.5
5
9
NA
NA
G190Q
60
 
0
0.3
>50
>50
NA
NA
Y188F
60
 
0.01
0.2
NA
NA
NA
NA
K103T
60
 
0.02
0.1
NA
NA
NA
NA
K103H
60
 
0
0.1
NA
NA
NA
NA
G190C
60
 
0
0.09
NA
NA
NA
NA
Y181F
60
 
0.02
0.06
NA
NA
NA
NA
Y181S
60
 
0.01
0.05
NA
NA
NA
NA
Y181G
60
 
0
0.05
NA
NA
NA
NA
G190V
60
 
0
0.05
NA
NA
NA
NA
G190T
60
 
0
0.03
NA
NA
NA
NA
K101E
45
0.2
8
2
3
1.5
2
P225H
45
0.02
4
2
3
1.2
NA
E138K
45
 
0.1
0.4
0.6
1.0
2
1.6
F227C
45
 
0
0.04
NA
NA
NA
NA
A98G
30
 
0.2
7
2
2
1.4
3
F227L
30
 
0.04
3
1.4
2
2
NA
K238T
30
 
0.05
2
3
2
1.4
NA
Y318F
30
 
0.1
2
NA
NA
NA
NA
M230I
30
 
0.03
0.1
NA
NA
NA
NA
L100V
30
 
0.04
0.09
NA
NA
NA
NA
N348I
15
 
0.1
14
NA
NA
NA
NA
V108I
15
 
0.4
9
2
3
1.0
0.9
H221Y
15
 
0.07
7
NA
NA
NA
NA
E138A
15
 
3
3
1.5
1.6
2
1.8
K101H
15
 
0.01
1
3
3
1.3
1.0
E138Q
15
 
0.03
1
1.4
1.0
NA
NA
E138G
15
 
0.3
0.7
2
1.4
3
1.7
V179F
15
0
0.3
0.9
3
2.0
0.4
V179L
15
 
0
0.2
NA
NA
NA
NA
E138R
15
 
0.01
0.03
NA
NA
NA
NA
V179D
10
 
2
3
3
5
3
1.8
V179E
10
 
0.8
1
NA
NA
NA
NA
K238N
10
 
0.06
0.4
NA
NA
NA
NA

    Footnotes:
  1. HIVDB Score: The highest score for NVP (nevirapine), EFV (efavirenz), ETR (etravirine), and RPV (rilpivirine).
  2. SDRM (Surveillance Drug Resistance Mutation): Nonpolymorphic DRMs that have been used for TDR surveillance (Bennett DE et al. PLoSOne 2009).
  3. Without Major DRMs: Primary DRMs are more likely to occur without additional DRMs. However, many co-occurring DRMs have primary roles in conferring resistance to different ARVs.
  4. Phenotypic Fold Resistance: The contribution of each DRM to reduced NNRTI susceptibility (fold increase in the NNRTI concentration required to inhibit a fixed virus inoculum by 50%) determined using published regression analyses. All results are based on susceptibility tests performed using the PhenoSense assay (Monogram, South San Francisco). The complete dataset used for the regression analyses is downloadable (HIVDB Genotype-Phenotype Dataset, http://hivdb.stanford.edu/cgi-bin/GenoPhenoDS.cgi. Red: Large contribution to reduced in vitro susceptibility. Pink: Statistically significant modest contribution to reduced in vitro susceptibility. Negative values indicate contribution to increased in vitro susceptibility.